Hyperphosphatemia News and Research

RSS

FDA grants marketing approval for Elitek

Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek (rasburicase) to be used for the initial management of plasma uric acid (PUA) levels in adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent elevations of plasma uric acid.

19 Oct 2009

Spectrum Pharmaceuticals acquires rights and IP for Renazorb

Spectrum Pharmaceuticals today announced that it has acquired 100% rights to RenaZorb (a family of compounds represented by SPI-014, also known as RZB-014), a lanthanum-based nanotechnology compound with potent and selective phosphate binding properties, for all human and non-human indications.

6 Aug 2009

Program for kidney disease patients effective for reducing serum phosphorus levels

Patients with end-stage renal disease (ESRD) who participated in an education program to limit their intake of phosphorus-containing food additives lowered their blood levels of the chemical, according to a study in the February 11 issue of JAMA, the Journal of the American Medical Association.

10 Feb 2009

Phosphorus binders help dialysis patients

For patients on dialysis, taking medications to reduce levels of the mineral phosphorus in the blood may reduce the risk of death by 25 to 30 percent, reports a study in the Journal of the American Society of Nephrology (JASN).

17 Dec 2008

Acologix demonstrates improved bone architecture in rat model of chronic kidney disease

Acologix, Inc. will present data indicating that its therapeutic product candidate AC-200 improved bone architecture in a rat model of chronic kidney disease.

8 Nov 2008

Forsenol reduces tablet burden on end stage renal disease patients with hyperphospatemia

According to data presented at the National Kidney Foundation's (NKF) 2006 clinical meeting in Chicago, IL, a conversion to the non-calcium phosphate binder FOSRENOL (lanthanum carbonate) from other phosphate binder therapies provides continued mean serum phosphorus control for end-stage renal disease (ESRD) patients with hyperphosphatemia, while significantly reducing their daily tablet burden and the total daily dose of phosphate binder medication.

26 Apr 2006

Hyperphosphatemia News and Research

FDA grants marketing approval for Elitek

Spectrum Pharmaceuticals acquires rights and IP for Renazorb

Program for kidney disease patients effective for reducing serum phosphorus levels

Phosphorus binders help dialysis patients

Acologix demonstrates improved bone architecture in rat model of chronic kidney disease

Forsenol reduces tablet burden on end stage renal disease patients with hyperphospatemia

Exploring the intersection of biology and proteomics

Unlocking the Secrets of Multiple Sclerosis Progression: Brain-Immune Cell Communication

Passing on Polycystic Ovary Syndrome: Health risks for male offspring of women with PCOS

Latest News